Amarin Corp Plc (AMRN)

[Whalatane]

LBL ..so to some of your pts
1) Unlikely legal action gets anywhere
2)Branded generic V will not make AMRN any $ ....agreeing to supply Apotex for their generic Vascepa .. with the product or the API supply via their existing supply agreements with Nisshan ? might .
3) OTC and branded combo are NOT going to work.
4) Hikma will have 180 day exclusivity ...first mover advantage so harder for other generic to carve out a market of any size
5) 800 sales reps still have their jobs ....yep until Hikma demonstrates they have the API supply and can scale up.
6) Baker Bros will wait for the EU market or a buy out offer to appear .

Actual rather than a " sell the news " day ....the day Hikma launches might be a " buy the news "type of day

Kiwi